180 related articles for article (PubMed ID: 31351663)
1. Current treatment of myeloproliferative neoplasias: three scenarios.
Xicoy B; Zamora L
Med Clin (Barc); 2020 Feb; 154(4):131-133. PubMed ID: 31351663
[No Abstract] [Full Text] [Related]
2. Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Green MR; Newton MD; Fancher KM
Am J Clin Oncol; 2016 Feb; 39(1):76-84. PubMed ID: 24351780
[TBL] [Abstract][Full Text] [Related]
3. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
4. [Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion].
Usui N; Miyamura K; Arai A; Motomura S; Yokoyama M
Nihon Naika Gakkai Zasshi; 2007 Jul; 96(7):1434-55. PubMed ID: 17682432
[No Abstract] [Full Text] [Related]
5. A phase 1 study of the Janus kinase 2 (JAK2)
Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
[TBL] [Abstract][Full Text] [Related]
6. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
[No Abstract] [Full Text] [Related]
7. The management of elderly patients with myeloproliferative disorders.
Tura S
Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
[No Abstract] [Full Text] [Related]
8. Novel therapeutics in myeloproliferative neoplasms.
Venugopal S; Mascarenhas J
J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
[TBL] [Abstract][Full Text] [Related]
9. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
10. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
Appelbaum FR
Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
[TBL] [Abstract][Full Text] [Related]
11. Asciminib in chronic myeloid leukemia: many questions still remain to be answered.
Eşkazan AE
Blood Cancer J; 2021 Apr; 11(4):81. PubMed ID: 33927187
[No Abstract] [Full Text] [Related]
12. Jak-2 positive myeloproliferative neoplasms.
Muxí PJ; Oliver AC
Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatments for classical myeloproliferative neoplasms.
Vannucchi AM; Harrison CN
Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
[TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
Tefferi A
Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
[TBL] [Abstract][Full Text] [Related]
15. Interferon in the treatment of myeloproliferative diseases.
Silver RT
Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
[TBL] [Abstract][Full Text] [Related]
16. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
[No Abstract] [Full Text] [Related]
17. Asciminib as a new option in the treatment of chronic myeloid leukemia.
İbiş B; Tiribelli M; Eşkazan AE
Future Oncol; 2021 Dec; 17(36):5003-5005. PubMed ID: 34791894
[No Abstract] [Full Text] [Related]
18. Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study.
Chornenki NLJ; Siegal DM; Qamar K; Woolgar S; Rangarajan S; Karampatos S; Leong DP; Hillis CM
Leuk Res; 2022 Feb; 113():106788. PubMed ID: 35042128
[No Abstract] [Full Text] [Related]
19. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
20. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]